Warning Letter Wednesday Posts
A weekly exploration of FDA warning letters and enforcement trends
Takeaway -
Remove COVID claims including on YouTube
Takeaway -
Expect arterial health claims to be cited in the future
Takeaway -
Study citations are marketing
Takeaway -
Discussing ingredient benefits is marketing
Takeaway -
Do not engage with customer “disease” testimonials
Takeaway -
Product claims must be compliant
Takeaway -
Discussing cholesterol or LDL levels is a disease claim
Takeaway -
CBD enforcement is top of mind for FDA
Takeaway -
Ingredient research can be considered a marketing claim
Takeaway -
Common labeling errors can be avoided
Takeaway -
Distributors are responsible for the products they sell
Takeaway -
Discussing ingredient benefits is a marketing claim